Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Melissa Andel, Principal and Founder of CommonHealth Solutions to take a closer look at the recent CMS guidance on drug price negotiation for 2026.
Health care expert Fred Goldstein sits down with Melissa Andel, principal and founder of CommonHealth Solutions, to discuss the long-awaited launch of Humira biosimilars and what Amgen’s pricing strategy means for patients and payers.
An AMCP Webinar hosted by FormularyDecisions®
The product review process is complex and can vary between organizations. Join us as our expert panel outlines best practices for conducting a comprehensive product review. Our panel represents the managed care organization and biopharma company viewpoints to discuss current challenges and opportunities to streamline the product review process; including ways to incorporate digital tools.
2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
During this sponsored webinar, we will overview Alzheimer's Disease (AD), discuss key considerations during the patient journey, and examine the potential impact of early intervention on the financial burden associated with AD.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Jennifer Graff, Senior Director of Professional Affairs at AMCP, to discuss trends to be watching regarding digital therapeutics and managed care pharmacy in 2023.
The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
Andrey Ostrovsky, MD, FAAP, and Lisa Palko, PharmD, discuss the ADHD landscape, challenges, and progress, including Akili's digital therapeutics value proposition as the first FDA-authorized prescription video game treatment.
